The annual Medicaid Drug Rebate Program (MDRP) Summit once again proved to be a pivotal gathering of regulators, legal experts, and industry leaders. With new policy shifts, compliance challenges, and ongoing litigation, this year’s sessions underscored the complexity of the Medicaid, Medicare and 340B landscape—and the critical need for proactive strategies to stay ahead.
Keynote Spotlight: 340B Program Update
The keynote session, led by Chantelle V. Britton, Director of the Office of Pharmacy Affairs (OPA), offered an in-depth look at the evolving 340B Program.
- OPA reaffirmed its mission to support affordable care for vulnerable patients through partnerships with over 14,000 covered entities and 800 manufacturers.
- A central focus was the 340B rebate model pilot program, which has already attracted 1,100+ public comments. This pilot aims to test how rebate structures could improve program efficiency and compliance.
- Auditing and compliance remain a priority: since 2012, OPA has conducted more than 2,400 covered entity audits and 51 manufacturer audits, with frequent findings tied to ceiling price violations and pricing data gaps
- OPA also emphasized the importance of good faith efforts to resolve disputes before escalation, with the Administrative Dispute Resolution (ADR) process available when needed
The keynote message was clear: compliance, transparency, and collaboration are critical for ensuring the 340B program continues to serve its intended purpose.
Legal and Regulatory Perspectives
Lawyer-led panels and policy experts shed light on the evolving compliance environment and the legal risks that manufacturers and covered entities face:
- CMS and IRA Provisions: The new rules under the Inflation Reduction Act (IRA) intersect with Medicaid and 340B, requiring careful attention to ceiling price calculations, duplicate discount avoidance, and evolving rebate models
- Bona Fide Service Fees: Proposed rule changes could redefine how these fees are evaluated, requiring independent third-party valuation, Fair Market Value Determination, and stricter documentation, significantly increasing the compliance burden.
- Most Favored Nation (MFN) and International Reference Pricing: Several panels explored how international reference pricing concepts continue to resurface in policy debates, despite unresolved legal and operational hurdles
- Dispute Resolution and Case Law: Industry lawyers noted recent court decisions shaping how agencies enforce rebate rules, stressing the importance of documenting assumptions and maintaining clear audit trails
Industry Insights and Strategic Responses
Beyond policy mechanics, industry experts stressed the operational and strategic implications for manufacturers, payers, and providers:
- Pricing Strategy Under Pressure: With inflationary rebates, maximum fair price, MFN discussions, and 340B growth, manufacturers face a “gross-to-net crunch” requiring early scenario planning and adaptive contracting strategies
- Telehealth and Direct-to-Patient Models: Emerging access models offer opportunities but raise compliance challenges around fraud and abuse laws, consumer protection, and data privacy
- Engagement with Agencies: Multiple speakers urged stakeholders to bring credible, data-driven proposals when engaging with CMS, OPA, or HHS—rather than generic feedback—highlighting the importance of credibility in advocacy
Moving Forward with Northridge
The MDRP Summit stressed what many of us already know: Medicaid and Medicare, 340B, and government pricing are more complicated than ever. With overlapping regulations, ongoing litigation, and programs like the 340B rebate model, stakeholders need both compliance discipline and strategic foresight to succeed.
At Northridge, we partner with manufacturers to navigate these complexities with clarity. From 340B audits to rebate modeling, from contracting strategies to regulatory monitoring, our team ensures you’re not only compliant but positioned for long-term success.
Reach out to Northridge to explore how we can support your organization during these dynamic times.
